JP2021506813A - 神経筋障害の治療のためのフェノキシ酸 - Google Patents

神経筋障害の治療のためのフェノキシ酸 Download PDF

Info

Publication number
JP2021506813A
JP2021506813A JP2020532801A JP2020532801A JP2021506813A JP 2021506813 A JP2021506813 A JP 2021506813A JP 2020532801 A JP2020532801 A JP 2020532801A JP 2020532801 A JP2020532801 A JP 2020532801A JP 2021506813 A JP2021506813 A JP 2021506813A
Authority
JP
Japan
Prior art keywords
group
substituted
acid
optionally
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020532801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506813A5 (https=
Inventor
ペデルセン，トーマス ホルム
ペデルセン，トーマス ホルム
ジェイ．エス．クヌッセン，ラース
ケリー，ニコラス
ブロック‐リップス，マーティン
オルセン，クラウス エルスボルグ
オルセン，クラウス エルスボルグ
ラベル，マーク
ニールセン，オレ ベッガード
ニールセン，オレ ベッガード
クマール，ラジェシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMD Pharma AS
Original Assignee
NMD Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMD Pharma AS filed Critical NMD Pharma AS
Publication of JP2021506813A publication Critical patent/JP2021506813A/ja
Publication of JP2021506813A5 publication Critical patent/JP2021506813A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020532801A 2017-12-14 2018-12-14 神経筋障害の治療のためのフェノキシ酸 Pending JP2021506813A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598940P 2017-12-14 2017-12-14
US62/598,940 2017-12-14
EP18151605 2018-01-15
EP18151605.5 2018-01-15
PCT/EP2018/084980 WO2019115777A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (2)

Publication Number Publication Date
JP2021506813A true JP2021506813A (ja) 2021-02-22
JP2021506813A5 JP2021506813A5 (https=) 2022-01-06

Family

ID=64661403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020532801A Pending JP2021506813A (ja) 2017-12-14 2018-12-14 神経筋障害の治療のためのフェノキシ酸

Country Status (12)

Country Link
EP (1) EP3723745B1 (https=)
JP (1) JP2021506813A (https=)
KR (1) KR20200099146A (https=)
CN (1) CN111587109A (https=)
AU (1) AU2018382597B2 (https=)
CA (1) CA3085226A1 (https=)
IL (1) IL274744B2 (https=)
MX (1) MX2020005398A (https=)
SG (1) SG11202005359TA (https=)
TW (1) TWI794369B (https=)
WO (1) WO2019115777A1 (https=)
ZA (1) ZA202002936B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025637A2 (pt) * 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
WO2024121130A1 (en) 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2024121129A1 (en) * 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases
WO2025196206A1 (en) 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536484A (ja) * 2002-06-26 2005-12-02 コレア リサーチ インスティテュート オブ ケミカル テクノロジー 光学活性（ｒ）−アリールオキシプロピオン酸エステル誘導体の製造方法
WO2016202341A1 (en) * 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1586463A (en) 1976-08-02 1981-03-18 Shell Int Research Herbicidal compositions
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
TW201720437A (zh) * 2015-10-29 2017-06-16 東北泰克諾亞奇股份有限公司 肌萎縮性疾病治療劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536484A (ja) * 2002-06-26 2005-12-02 コレア リサーチ インスティテュート オブ ケミカル テクノロジー 光学活性（ｒ）−アリールオキシプロピオン酸エステル誘導体の製造方法
WO2016202341A1 (en) * 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRACCHIOLLA, G. ET AL.: "Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid", CHEMMEDCHEM, vol. 2(5), JPN6022047233, 2007, pages 641 - 654, ISSN: 0005063969 *
PERRONE, M. G. ET AL.: "Reaction of caesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analo", TETRAHEDRON: ASYMMETRY, vol. 16(4), JPN6022047231, 2005, pages 783 - 792, ISSN: 0005063968 *
PUSCH, M. ET AL.: "Pharmacological Characterization of Chloride Channels Belonging to the ClC Family by the Use of Chir", MOLECULAR PHARMACOLOGY, vol. 58(3), JPN7022005242, 2000, pages 498 - 507, ISSN: 0005063970 *

Also Published As

Publication number Publication date
KR20200099146A (ko) 2020-08-21
CN111587109A (zh) 2020-08-25
IL274744B2 (en) 2023-02-01
IL274744B (en) 2022-10-01
TWI794369B (zh) 2023-03-01
EP3723745B1 (en) 2024-06-19
SG11202005359TA (en) 2020-07-29
CA3085226A1 (en) 2019-06-20
AU2018382597A1 (en) 2020-07-02
EP3723745A1 (en) 2020-10-21
ZA202002936B (en) 2024-11-27
IL274744A (en) 2020-07-30
MX2020005398A (es) 2020-08-17
AU2018382597B2 (en) 2024-04-04
TW201938525A (zh) 2019-10-01
EP3723745C0 (en) 2024-06-19
WO2019115777A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
JP2021506813A (ja) 神経筋障害の治療のためのフェノキシ酸
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
EP3724173B1 (en) Compounds for the treatment of neuromuscular disorders
JP7287607B6 (ja) 神経筋障害の治療のためのフェノキシ酸
US12168643B2 (en) Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) Compounds for the treatment of neuromuscular disorders
US20220388938A1 (en) Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) Compounds for the treatment of neuromuscular disorders
US20190183812A1 (en) Compounds For The Treatment Of Neuromuscular Disorders
HK40029101B (en) Compounds for the treatment of neuromuscular disorders
HK40029101A (en) Compounds for the treatment of neuromuscular disorders
AU2009292498A1 (en) Novel pharmaceutical composition for treatment of nociceptive pain

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230523